Evaluation of the Safety of Lead Compounds for Allergic Asthma

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1122668

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Asthma is one of the most common chronic respiratory diseases in developed countries and is typically treated with corticosteroids which provide symptomatic relief and coarse non-specific treatment of the underlying disease. We are pursuing innovative therapies by targeting a different enzyme, HPGD2S, involved in the inflammatory mechanisms of asthma. We have developed potent, anti-inflammatory drug candidates and aim to profile the safety of these compounds before entering clinical studies.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2018

Funding Scheme: Development Grants

Funding Amount: $310,568.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Molecular Medicine

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

allergic disease | asthma | drug toxicity | inhibitors | safety

Related Links